Skip to search formSkip to main contentSkip to account menu

CMC-544

Known as: CMC544, WAY-207294, Way 207294 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Inotuzumab Ozogamicin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
Review of Antibody-Drug Conjugates, Methods in Molecular Biology series
Antibody-drug conjugates (ADCs) represent an exciting and promising therapeutic approach for the treatment of cancers. The US… 
2011
2011
Inotuzumab ozogamicin (IO; CMC544), a CD22 monoclonal antibody attached to calicheamycin, produces complete response (CR) plus complete marrow response (mCR) of greater than 50% in refractory relapse…
6507 Background: Patients (pts) with R-R ALL have a poor prognosis. CD22 is highly expressed in ALL. IO is active in CD22… 
Highly Cited
2010
Highly Cited
2010
Phase I study of inotuzumab ozogamicin (CMC‐544) in Japanese patients with follicular lymphoma pretreated with rituximab‐based therapy
Inotuzumab ozogamicin (CMC‐544), an antibody‐targeted chemotherapeutic agent composed of an anti‐CD22 antibody conjugated to… 
2010
2010
Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) + Rituximab In Relapsed DLBCL Patients Followed by Stem Cell Transplantation: Preliminary Safety and Efficacy
Abstract 2883 Background: Inotuzumab ozogamicin (CMC-544) is a humanized anti-CD22 antibody conjugated to calicheamicin, a… 
Review
2010
Review
2010
Inotuzumab ozogamicin as novel therapy in lymphomas
Importance of the field: More than 65,000 cases of non-Hodgkin's lymphoma are estimated to have been diagnosed in 2009; the… 
2009
2009
CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells
We studied the effect of CMC-544, the calicheamicin-conjugated anti-CD22 monoclonal antibody, used alone and in combination with… 
2009
2009
CMC-544 (inotuzumab ozogamicin): A CD22-targeted immunoconjugate of calicheamicin
CMC-544 (Inotuzumab ozogamicin) is a CD22-targeted immunoconjugate of calicheamicin currently being evaluated in phase III… 
2008
2008
Safety and Clinical Activity of the Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) in Combination with Rituximab in Follicular Lymphoma or Diffuse Large B-Cell Lymphoma: Preliminary Report…
Inotuzumab ozogamicin (CMC-544) is an antibody-targeted chemotherapy agent composed of a humanized CD22 antibody, conjugated to… 
2006
2006
Clinical Activity of the Immunoconjugate CMC-544 in B-Cell Malignancies: Preliminary Report of the Expanded Maximum Tolerated Dose (MTD) Cohort of a Phase 1 Study.
Introduction: CMC-544 is an antibody-targeted chemotherapy agent composed of a humanized antibody that specifically targets the… 
2005
2005
Preliminary Report of a Phase 1 Study of CMC-544, an Antibody-Targeted Chemotherapy Agent, in Patients with B-Cell Non-Hodgkin’s Lymphoma (NHL).
Introduction: CMC-544 is an antibody-targeted chemotherapy agent composed of a monoclonal antibody, which specifically targets… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)